Weight loss Novo Nordisk - Search News

Novo Nordisk spikes

Hosted on MSN · 2d

Novo Nordisk reports 22% weight loss in early subcutaneous amycretin trial

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying people with obesity or overweight treated with the drug achieved a 22% weight loss after 36 weeks.

Kiplinger on MSN · 2d

Novo Nordisk Stock Surges On Weight Loss Drug Data and Analysts Say It's Still a Buy

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight loss drug. Here's what you need to know.

Seeking Alpha on MSN · 2d

Novo Nordisk spikes as novel obesity drug causes up to 22% of weight loss

Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here.

2don MSN

Novo Nordisk Shares Surge on New Obesity Drug Results

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

20h

Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

2don MSN

Why Novo Nordisk Stock Jumped a Lucky 7.7% Today

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results